New hope for nigerian women with aggressive breast cancer: targeted drug combo under study

NCT ID NCT06348134

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of anti-HER2 drugs (trastuzumab emtansine, pertuzumab, and docetaxel) plus hormone therapy (tamoxifen or letrozole) given before and after surgery in 74 Nigerian women with HER2-positive breast cancer. The main goal is to see if the cancer disappears completely by the time of surgery. The study also tracks side effects to assess safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab emtansine, pertuzumab, docetaxel, tamoxifen, letrozole
What this could lead to: If successful, this could show that a tailored anti-HER2 drug combination is safe and effective for Nigerian women, potentially improving breast cancer outcomes in this population.
What could go wrong: This is a small, early-phase trial (74 participants) with no control group, so results may not be conclusive. Side effects from chemotherapy and anti-HER2 drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HER2-POSITIVE BREAST CANCER HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST

Contacts and locations

Locations

Lagos State University Teaching Hospital
RECRUITING

Ikeja, Lagos, 100271, Nigeria
Lagos University Teaching Hospital
RECRUITING

Yaba, Lagos, 100254, Nigeria
Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC)
RECRUITING

Ile-Ife, Osun State, 220005, Nigeria
University of Ibadan Hospital
RECRUITING

Ibadan, Oyo State, 200285, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.